In our previous study, we demonstrated that targeting three epithelial-related markers, EpCAM, epidermal growth factor receptor (EGFR), and MET, increased the CTC detection rate in patients with head and neck squamous-cell carcinoma (HNSCC) [12]. This evidence concerns the gene MET and head and neck squamous cell carcinoma.